Quantcast Archives 0407.html
Search by tag or site Login to my blog ? Start my own blog














TheMoneyBlogs
Home
About
Create your own blog
Contact us
Vote for this blog!

BioHealth Investor

BioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network.

April 2007

Thailand Not A Threat To Pharmaceutical Industry
Medical Firms Make Product Placement Deals With Er, Grey's Anatomy
Cramer's "ultimate Defensive Portfolio" Of Medical Stocks
Omrix’s Biosurgical Products
Nfl Stars Back New Supplement Delivery System
Getting Physicians To Think Seriously About Radiation Exposure
New Eye Mask For Growing Blepharoplasty Market
Dendreon: Countdown To Fda
Palomar Medical: To Dominate The Aesthetic Laser Market?
Westaim Management To Look At ‘strategic Alternatives’
Align Technology Blows Through Estimates
High Hopes For New Prostate-cancer Test
Up On The Hill - Pdufa Testimony
Nutrisystem's Impressive Quarter
Cryocor Raises $5.45 Million In Private Placement
Iapyx Introduces Catheter Stabilization Devices
Purdue Pharma Tries To Salvage 30-month Stay In Oxycontin Case Against Mallinckrodt
Strongest Quarter Ever For Life Sciences Venture Funding
Wal-mart General Hospital
Alphamd: An Investor's Lens To The Medical World
Biowatch Alert: Provectus Jumps 15% On 6x Volume
Medimmune Sold: Icahn 1, Management 0
Biowatch Alert: Oxigene Gains On 10x Volume
Short Squeezing Biotechs
Abbott Wins Preliminary Injunction Against Sandoz In Biaxin Xl Case
Rosetta Genomics: Final Decision, Buy Or Hold Off?
Smart Buys: Osi Systems And Viasys Healthcare
Fda Okays Cepheid’s Test For Msra
Aarp Quest For Health Care 'leverage' Doesn't Bother Ny Times
Who's In Favor Of Safer Drugs?
Fda Refuses To Approve Any Andas For Generic Norvasc Besides Mylan's
Aquasonix Therapy Hits Hospitals And Rehab Centers
Pfizer Looks Like A Bond Replacement: Earnings Preview
Pharmaceutical Industry Slow To Embrace New Media: Feeds & Aggregators
Fda Seizes Shelhigh Devices
Merck Gaining Respectability Again?
Targacept: Late Day Volume Surge Deserves Attention
Exegenics: An Exciting New Approach To Macular Degeneration
Oligonucleotides: An Overview Of Their Therapeutic Potential
Signalife Contracts 25 Reps For Ecg Monitoring System
Cervical Cancer Vaccine Wars Heating Up
Cell Genesys Showing New Positive Study Data
What A Ban On Dtc Means For Public Relations
Boston Scientific Begging For Good News
‘glaring Lack’ Of Capital For Connecticut Medical Technology Start Ups
Amgen: No Lesson Learned From Merck
Bespak To Acquire Emergent For $38m
District Court Dismisses Merck's Fosamax Suit Against Apotex
Peregrine "compares" To Avastin
Biotech Stocks Following Fda Extensions
Biowatch Alert: Heska Jumps On 5x Volume, No News
Rosetta Genomics Partners: What’s Yours Is Mine
Biotech Daily Review: Dyax Jumps On Positive Data
Sinobiomed Wins Approval Of Recombinant Growth Factor
Someone At Merck Is Crazy
Biotech Daily Review: Medimmune Puts Itself Up For Sale
Tycoon To Acquire 25% Stake In Sanguibiotech
Third Point Increases Heat On Ceo Of Pdl Biopharma
Cramer Looking For The Next Dendreon
U.s. Stem Cell Policy - Ceding The Competitive Edge
Medimmune Decides To Pursue A Sale
Biowatch Alert: Exegenics Jumps 10% On Strong Volume, No News!
Ipo Watch: Simcere Supplies High-end Generics In China
Biotech Daily Review: Genentech Beats Estimates Slightly
Out Of Dendreon; Another Chance In May
Andover Medical Closes $5.6m Private Financing
Cell Genesys Slips New Holders A Mickey
Dendreon Downgraded, Sort Of.....
Ex-endocare Execs Indicted
Amgen Cfo Walks Out; Any More Execs Leaving?
Hydromedix To Raise $250k
Leaving Pdufa Alone
Adolor: Is There Anything Left?
Biotech Daily Review: Entereg From Gsk And Adolor Fails Test
Tepha Flexes Marketing Muscle
J&j Buys Chinese Cosmetics Company For $300m
Vaino's Biotech Corner Portfolio Update
Biowatch Alert: Repligen Jumps On Higher Volume, No News!
Biotech Weekly Review: Biotech In Positive Territory For 2007
Micro Rnas: The Last Frontier Of Medicine?
Bioveris Acquisition Underscores Importance Of Diagnostics
Biotech Daily Review: Bidding War Erupts For Biosite
Jim Cramer On Dendreon
Biotech Daily Review: Roche Buys Bioveris For $600m
Xtent: Drug-eluting Stent Shows Positive Clinical Results
Nanogen Jumps On Gsa Contract
Medarex Stock Options Activity Resembles Dendreon's
Pdufa Dollars Up, Warning Letters Down
Biotech Implosion: Icagen Drops On Trial Termination
Biotech Daily Review: Cell Genesys Climbs On Gvax Results
Key Stem Cell Patents Revoked
"60 Minutes" Takes 13 Minutes To Attack Drug Companies
Stem Cell Stocks Gain On British Study, Geron Gives Some Back
Biotech Daily Review: Roche Picks Up Antibody Firm For $56.5 Million
Synta Pharmaceuticals: To Buy Or Not To Buy?
China Biotech Review: Cancer Therapeutics Sues Partner Peregrine

<< Home

Stock Quote or
Examples
Underground Trading - Sat May 10, 2008 04:02PM
This is an update on my speculative long term position p [read more]
Morpheus Trading - Mon May 12, 2008 04:25AM
NOTE: Please click on the charts below to enlarge them if [read more]
Millionaire Now! by Larry Nusbaum - Mon May 12, 2008 04:54AM
MORNING MARKET COMMENTARYfor Monday, May 12, 2008Weak Financ [read more]

PREMIER SPONSORED LINKS

Most Visited Blogs | Most Popular Blogs | Most Recent Blogs | Contact Us | Terms and conditions | Privacy Policy

The columns, articles, message board posts and any other features provided on TheMoneyBlogs.com are provided for personal finance, education and investment information and are not to be construed as investment advice. Under no circumstances does the information in this content represent a recommendation to buy, sell or hold any security. The views and opinions expressed in an article or column are the author's own and not necessarily those of TheMoneyBlogs.com and there is no implied endorsement by TheMoneyBlogs.com of any advice or trading strategy. The analysts and employees or affiliates of TheMoneyBlogs.com may hold positions in the stocks or industries discussed here. Your use of this and all information contained on TheMoneyBlogs.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

Copyright © 2008 The Connors Group, Inc.